Products & Services · Total revenues
Royalty revenue — Total revenues
Alnylam Pharmaceuticals Royalty revenue — Total revenues decreased by 20.2% to $48.97M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 85.0%, from $26.47M to $48.97M. Over 4 years (FY 2021 to FY 2025), Royalty revenue — Total revenues shows an upward trend with a 247.3% CAGR.
Analysis
Metric ID:
alny_segment_royalty_revenue_total_revenuesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $347K | $453K | $396K | $442K | $2.28M | $2.74M | $2.72M | $6.5M | $7.21M | $9.91M | $17.02M | $10.62M | $22.4M | $23.39M | $35.39M | $26.47M | $39.98M | $46.2M | $61.37M | $48.97M |
| QoQ Change | — | +30.5% | -12.6% | +11.6% | +415.4% | +20.4% | -1.0% | +139.4% | +10.8% | +37.5% | +71.9% | -37.6% | +110.9% | +4.4% | +51.3% | -25.2% | +51.1% | +15.6% | +32.8% | -20.2% |
| YoY Change | — | — | — | — | +556.5% | +505.3% | +585.6% | >999% | +216.3% | +261.2% | +527.0% | +63.4% | +210.9% | +136.1% | +107.9% | +149.2% | +78.5% | +97.6% | +73.4% | +85.0% |
Range$347K – $61.37M
CAGR+183.5%
Avg YoY Growth+314.0%
Median YoY Growth+180.0%
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's royalty revenue — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported royalty revenue — total revenues of $48.97M in Q1 2026.
- How has Alnylam Pharmaceuticals's royalty revenue — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's royalty revenue — total revenues increased by 85.0% year-over-year, from $26.47M to $48.97M.
- What is the long-term trend for Alnylam Pharmaceuticals's royalty revenue — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's royalty revenue — total revenues has grown at a 247.3% compound annual growth rate (CAGR), from $1.2M to $174.02M.